Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

2 Apr 2009

FDA provides positive review of InNexus' lead preclinical drug candidate

3 Mar 2009

B-cell clones as early markers for chronic lymphocytic leukemia

Testing of blood specimens may detect abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current issue of the New England Journal of Medicine.

22 Feb 2009

Ingredient in cough medicine could treat prostate cancer

A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer.

22 Dec 2008

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Networks of interactive genes may predict Leukemia's development

Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.

8 Dec 2008

New chemotherapy pill shows promise for stubborn lymphomas

A new chemotherapy pill is showing early success in treating people with stubborn lymphomas, according to scientists at the University of Rochester Medical Center. Doctors reported that the drug is halting disease in nearly half of the patients with chronic lymphocytic leukemia, and in patients with more aggressive lymphoma as well.

8 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

8 Dec 2008

Discovery of novel drug target for chronic lymphocytic leukemia

Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.

24 Nov 2008

NCI sponsors Canadian cold/flu remedy trial in leukemia patients

Cancer patients, with their weakened immune systems, are particularly vulnerable when the cold and flu season hits. The National Cancer Institute (NCI), part of the National Institutes of Health and the world's most prestigious cancer research body, is sponsoring a landmark trial to evaluate if a unique Canadian cold remedy - ginseng extract COLD-FX - can help.

18 Nov 2008

COLD-FX remedy undergoes NCI-sponsored trial in leukemia patients

Cancer patients - with their weakened immune systems - are particularly vulnerable when the cold and flu season hits.

17 Nov 2008

Novel leukemia therapy shows promise for high-risk patients

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

4 Nov 2008

Genmab announces four studies of ofatumumab in chronic lymphocytic leukemia

Genmab A/S announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year.

25 Aug 2008

Researchers find way to make tumor cells more sensitive to hyperthermia-enhanced radiation therapy

Tumors have a unique vulnerability that can be exploited to make them more sensitive to heat and radiation, researchers at Washington University School of Medicine in St. Louis report.

6 May 2008

Pralatrexate for T-cell lymphoma

The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).

24 Apr 2008

Research reveals the signature of 70 genes controlled by two microRNAs

By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model.

24 Apr 2008

MaxCyte introduces large scale transfection technology - accelerates cell-based assay development

MaxCyte has announced the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology.

21 Apr 2008